HOME > Articles >

Korean J Gastroenterol  <  Volume 71(6); 2018 <  Articles

Korean J Gastroenterol 2018; 71(6): 308-314  https://doi.org/10.4166/kjg.2018.71.6.308
Clinical Implication of Sarcopenia in Patients with Inflammatory Bowel Disease
Seong-Eun Kim
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
Published online: June 25, 2018.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Recent studies have shown that inflammatory bowel disease (IBD) patients are affected by altered body composition, especially low muscle mass or sarcopenia. Detection of sarcopenia is important, as it can independently predict osteopenia, sarcopenic obesity, and poor disease outcomes during IBD progress. The challenges are needed to identify diagnostic and managing strategies for sarcopenia in IBD to improve disease outcomes and increase the quality of life in patients with IBD.
Keywords: Inflammatory bowel disease; Sarcopenia; Body composition; Obesity; Bone diseases, metabolic
Tables

Categories of Sarcopenia4

Primary sarcopenia
 Age-related sarcopenia No other cause evident except ageing
Secondary sarcopenia
 Activity-related sarcopenia Can result from bed rest, sedentary lifestyle, deconditioning or zero-gravity conditions
 Disease-related sarcopenia Associated with advanced organ failure (heart, lung, liver, kidney, brain), inflammatory disease, malignancy or endocrine disease
 Nutrition-related sarcopenia Results from inadequate dietary intake of energy and/or protein, as with malabsorption, gastrointestinal disorders or use of medications that cause anorexia
References
  1. Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017;36:321-347.
    Pubmed CrossRef
  2. Hebuterne X, Filippi J, Schneider SM. Nutrition in adult patients with inflammatory bowel disease. Curr Drug Targets 2014;15:1030-1038.
    Pubmed CrossRef
  3. Schneider SM, Al-Jaouni R, Filippi J, et al. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2008;14:1562-1568.
    Pubmed CrossRef
  4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010;39:412-423.
    Pubmed KoreaMed CrossRef
  5. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997;127:990S-991S.
    Pubmed CrossRef
  6. Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci 1997;52:B267-276.
    Pubmed CrossRef
  7. Clark BC, Manini TM. What is dynapenia? Nutrition 2012;28:495-503.
    Pubmed KoreaMed CrossRef
  8. Grimby G, Saltin B. The ageing muscle. Clin Physiol 1983;3:209-218.
    Pubmed CrossRef
  9. Ryu SW. Clinical characteristics of sarcopenia and cachexia. J Clin Nutr 2017;9:2-6.
    CrossRef
  10. Kim TN. Diverse abnormal body composition penotypes: interaction between muscle, fat, and bone. Korean J Obes 2015;24:9-16.
    CrossRef
  11. Kim TN, Park MS, Yang SJ, et al. Body size phenotypes and low muscle mass: the Korean sarcopenic obesity study (KSOS). J Clin Endocrinol Metab 2013;98:811-817.
    Pubmed CrossRef
  12. Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011;2:1-3.
    Pubmed KoreaMed CrossRef
  13. Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD:Malnutrition and/or sarcopenia? A practical guide. Gastroenterol Res Pract 2017;2017:8646495.
    Pubmed KoreaMed CrossRef
  14. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003;58:M911-916.
    Pubmed CrossRef
  15. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457-465.
    Pubmed CrossRef
  16. Perandini LA, de Sá-Pinto AL, Roschel H, et al. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Autoimmun Rev 2012;12:218-224.
    Pubmed CrossRef
  17. Vettor R, Milan G, Franzin C, et al. The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Endocrinol Metab 2009;297:E987-998.
    Pubmed CrossRef
  18. van Langenberg DR, Della Gatta P, Hill B, Zacharewicz E, Gibson PR, Russell AP. Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. J Crohns Colitis 2014;8:626-634.
    Pubmed CrossRef
  19. Hamrick MW. The skeletal muscle secretome: an emerging player in muscle-bone crosstalk. Bonekey Rep 2012;1:60.
    Pubmed KoreaMed CrossRef
  20. Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia:common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:895-906.
    Pubmed CrossRef
  21. Sylvester FA, Gordon CM, Thayu M, et al. Report of the CCFA pediatric bone, growth and muscle health workshop, New York City, November 11-12, 2011, with updates. Inflamm Bowel Dis 2013;19:2919-2926.
    Pubmed CrossRef
  22. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006;2:35-43.
    Pubmed CrossRef
  23. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-913.
    Pubmed CrossRef
  24. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006;99:824-834.
    Pubmed CrossRef
  25. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196-208.
    Pubmed CrossRef
  26. Binkley N, Buehring B. Beyond FRAX: it's time to consider "sarco-osteopenia". J Clin Densitom 2009;12:413-416.
    Pubmed CrossRef
  27. Mager DR, Carroll MW, Wine E, et al. Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur J Clin Nutr 2018;72:623-626.
    Pubmed CrossRef
  28. Zoico E, Corzato F, Bambace C, et al. Myosteatosis and myofibrosis:relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr 2013;57:411-416.
    Pubmed KoreaMed CrossRef
  29. Heber D, Ingles S, Ashley JM, Maxwell MH, Lyons RF, Elashoff RM. Clinical detection of sarcopenic obesity by bioelectrical impedance analysis. Am J Clin Nutr 1996;64:472S-477S.
    Pubmed CrossRef
  30. Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia Is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis 2017;23:1182-1186.
    Pubmed CrossRef
  31. Bryant RV, Trott MJ, Bartholomeusz FD, Andrews JM. Systematic review: body composition in adults with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:213-225.
    Pubmed CrossRef
  32. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002;21:51-57.
    Pubmed CrossRef
  33. Olivier I, Théodorou V, Valet P, et al. Is Crohn's creeping fat an adipose tissue? Inflamm Bowel Dis 2011;17:747-757.
    Pubmed CrossRef
  34. Gambero A, Maróstica M, Abdalla Saad MJ, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 2007;13:1357-1364.
    Pubmed CrossRef
  35. Holt DQ, Moore GT, Strauss BJ, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn's disease recurrence. Aliment Pharmacol Ther 2017;45:1255-1264.
    Pubmed CrossRef
  36. Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ.. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther 2014;40:1202-1208.
    Pubmed CrossRef
  37. Ding NS, Malietzis G, Lung PFC, et al. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther 2017;46:883-891.
    Pubmed CrossRef
  38. Bamba S, Sasaki M, Takaoka A, et al. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS One 2017;12:e0180036.
    Pubmed KoreaMed CrossRef
  39. Zhang T, Cao L, Cao T, et al. Prevalence of sarcopenia and its impact on postoperative outcome in patients with Crohn's disease undergoing bowel resection. JPEN J Parenter Enteral Nutr 2017;41:592-600.
    Pubmed CrossRef
  40. Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. Sarcopenia is a novel predictor of the need for rescue therapy in hospitalized ulcerative colitis patients. J Crohns Colitis 2018 May 12. [Epub ahead of print]
    Pubmed KoreaMed CrossRef
  41. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014;20:2247-2259.
    Pubmed CrossRef
  42. Ding NS, Malietzis G, Hart AL. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. authors' reply. Aliment Pharmacol Ther 2018;47:142-143.
    Pubmed CrossRef
  43. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015;149:350-5.e2.
    Pubmed CrossRef
  44. Park SW. Sarcopenia of the old age. J Korean Endocr Soc 2007;22:1-7.
    CrossRef
  45. Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 2008;24:694-702.
    Pubmed CrossRef


This Article


Cited By Articles

Stats or Metrics
  • View: 494
  • Download: 592

Services
Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • thomson reuters
  • koreamed
  • crossref
  • google
  • synepse
  • kofst
  • DOAJ
  • ORCID